|Delayed - 10/25 02:13:25 pm|
Innocan Pharma Corporation Updates Its Progress in the Pre-Clinical Studies of Its CBD-Loaded Liposome Platform08/03/2021 | 07:16am
Innocan Pharma Corporation issue an update on its cutting-edge pre-clinical studies and on the development progress of its Liposome/CBD delivery platform (LPT). These studies are led by Dr. Ahuva Cern and Prof. Chezy Barenholz of The Hebrew University of Jerusalem. To date, Innocan completed two pre-clinical trials on animals. The first trial demonstrated no side effects, while the duration of a single intra-muscular injection resulted in the presence of a high level of CBD for at least 3 weeks in the plasma. In the second trial, the researchers observed the effect of CBD in a disease model of the central nervous system, while CBD was detected for a period of over 7 weeks, after 2 injections. To date, the research team is continuing these studies to enable submitting a peer reviewed scientific publication, including the data and conclusions from the first and second trial. The meaningful therapeutic efficacy demonstrated in the pre-clinical study led Innocan to initiate a third set of pre-clinical trials. These trials are aiming to examine additional indications for the LPT platform.
© S&P Capital IQ 2021
All news about INNOCAN PHARMA CORPORATION